IM Cannabis Corp.NASDAQ: IMCC

IM Cannabis Corp. Announces Third Quarter 2026 Financial Results

· Issued by IM Cannabis Corp. via PR Newswire

Summary by 6ix AI

IM Cannabis Corp., which runs a medical cannabis platform serving patients in Israel, reported revenue of C$1.65 million for the third quarter ended September 30, 2026, compared to C$5.08 million a year earlier. Total net loss was C$7.08 million, compared to C$3.87 million in the third quarter of 2025.

Key details

  • Gross loss for the third quarter ended September 30, 2026 was C$35,000.
  • For the first nine months ended September 30, 2026, revenue was C$8.96 million, compared to C$15.77 million in the same period of 2025, and total net loss was C$13.93 million, compared to C$3.88 million.
  • On September 29, 2026, the company completed the sale of its European-focused operations, including its German subsidiary Adjupharm GmbH, to Slil.com Holding Ltd., after a restructuring under which it kept its Israeli medical cannabis operations.
  • The sale consideration included a C$3 million advance payment and the assumption of certain liabilities of up to C$9.4 million. The company expects the sale to improve shareholders' equity by approximately C$3 million.
  • In September 2026, the company signed a non-binding agreement to acquire a 51% stake in Space Defense Innovations LLC (SDI), a Polish company in the unmanned aerial systems (drone) sector whose subsidiary BlueAero Group distributes tactical drone products made by BlueBird Aero Systems.

What’s still pending

  • The agreement to acquire 51% of Space Defense Innovations LLC is non-binding; the company is negotiating a definitive share purchase agreement with SDI's shareholders.
  • The approximately C$3 million improvement in shareholders' equity from the European sale is an expectation.

6ix AI wrote this summary from the release below and checked it against the release.

VANCOUVER, BC and GLIL YAM, Israel, Nov. 13, 2026 /PRNewswire/ -- IM Cannabis Corp. (the "Company") (NASDAQ: IMCC) announced its financial results for the third quarter and first nine months ended September 30, 2026.

For the third quarter of 2026, revenue totaled C$1.65 million, compared to C$5.08 million in the same period last year. The Company reported a gross loss of C$35,000 and a total net loss of C$7.08 million, compared to a net loss of C$3.87 million in the third quarter of 2025. For the first nine months of 2026, revenue totaled C$8.96 million, compared to C$15.77 million in the corresponding period of 2025, while total net loss amounted to C$13.93 million, compared to C$3.88 million.

In September 2026, the Company announced a non-binding agreement to acquire a 51% stake in Space Defense Innovations LLC (SDI), a Polish company operating in the unmanned aerial systems sector through its subsidiary BlueAero Group, which distributes tactical UAS products manufactured by BlueBird Aero Systems. The Company is currently negotiating a definitive share purchase agreement with SDI's shareholders.

Separately, the Company completed the sale of its European-focused operations, including its German subsidiary Adjupharm GmbH, to Slil.com Holding Ltd. on September 29, 2026, following a restructuring under which the Company's Israeli medical cannabis operations were retained. The transaction consideration included a C$3 million advance payment and the assumption of certain liabilities of up to C$9.4 million. The Company expects the transaction to improve shareholders' equity by approximately C$3 million.

The full Interim Financial Statements and Management's Discussion and Analysis are available on SEDAR+ and EDGAR.

About IM Cannabis Corp.

IM Cannabis Corp. (NASDAQ: IMCC) is an international company operating a medical cannabis platform serving patients in Israel.

The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms in Israel that enable the safe delivery and quality control of IMCC's products throughout the value chain.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, "forward-looking statements"). Forward-looking statements are often, but not always, identified by words such as "may", "will", "could", "would", "should", "expect", "intend", "anticipate", "believe", "plan", "estimate", "likely", "potential", "proposed" and similar expressions, or statements that events, conditions or results "may", "will", "could", "would" or "should" occur or be achieved.

Forward-looking statements in this press release include, without limitation, statements concerning the anticipated effect of the Transaction on the Company's shareholders' equity, working capital, consolidated liabilities, corporate structure and financial condition; the Company's intended focus on its retained Israeli medical cannabis operations; the Company's evaluation of additional opportunities; the anticipated accounting treatment and financial impact of the Transaction; and the realization of the expected financial and operational benefits of the Transaction.

Forward-looking statements are based on a number of assumptions, including that the Company's preliminary and unaudited estimates regarding the accounting and financial impact of the Transaction are materially accurate; that the accounting treatment of the Transaction will be consistent with management's current expectations; that the Company will realize the expected benefits of the Transaction; that no unanticipated liabilities, indemnification obligations, tax liabilities or post-closing claims will materially reduce those anticipated benefits; and that the Company will be able to operate and finance its retained Israeli business substantially as currently contemplated.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the risk that the anticipated improvement in shareholders' equity, working capital, consolidated liabilities, corporate structure or financial condition is not realized or is less than expected; the risk that the accounting treatment or financial impact of the Transaction differs from management's current expectations; the risk of purchase-price adjustments, post-closing claims, indemnification obligations, tax liabilities or disputes arising from the Transaction or the pre-closing reorganization; the risk that liabilities associated with IMC Holdings or the Target Subsidiaries differ from the amounts currently expected; the risk that the retained Israeli operations do not perform as expected; risks relating to the Company's liquidity position, going concern disclosure, debt obligations and ability to raise additional capital; the risk that the Company is unable to maintain or regain compliance with the continued listing requirements of Nasdaq Stock Market LLC; risks relating to regulatory changes, licensing, supply-chain constraints, competition, product liability and reliance on key personnel; war, conflict and civil unrest in Israel and the Middle East; and the other risks, uncertainties and factors described under the heading "Risk Factors" in the Company's annual report for the year ended December 31, 2025 and in the Company's subsequent public filings, which are available under the Company's issuer profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.

Forward-looking statements are made as of the date of this press release and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. The Company does not undertake any obligation to update any forward-looking statements, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Michal Efraty
Investor & Public Relations
michal@efraty.com

Oren Shuster, CEO
IM Cannabis Corp.
info@imcannabis.com

SOURCE IM Cannabis Corp.

View original source (PR Newswire)IM Cannabis Corp. on 6ix

Story so far

Earlier from IM Cannabis

Later from IM Cannabis

All IM Cannabis news releases